The Value of Surface Enhanced Laser Desorption/Ionization-Time of Flight Mass Spectrometry at the Diagnosis of Non-Small Cell Lung Cancer: A Systematic Review

Abstract

Numbers of studies used surface enhanced laser desorption/ionization-time of flight mass spectrometry (SELDI-TOF-MS) to find novel serum biomarkers for non-small cell lung cancer (NSCLC). It is arguable whether the SELDI technique has its value of diagnostic accuracy for NSCLC. The purpose of our study is to determine the diagnostic accuracy of SELDI-TOF-MS for diagnosing NSCLC. The Cochrane Central Register of Controlled Trials, MEDLINE, Pub Med, EMBASE, the Chinese Biomedical Literature Database, the China Academic Journals Full-text Database, and the Chinese Scientific Journals Database were searched systematically for potential studies. Reference lists of included studies and review articles were also reviewed. All studies that reported data on patients with a confirmed diagnosis of NSCLC and that compared the measurement of SELDI-TOF-MS with pathology standard were considered for inclusion. 11 studies were included in the systematic review. The ranges of the diagnostic value of SELDI-TOF-MS for NSCLC were as follows: sensitivity (SEN) was 0.70~1.00; specificity (SPE) was 0.68~1.00; positive likelihood ratio (PLR) was 2.23~23.14; negative likelihood ratio (NLR) was 0.04~0.43; and diagnostic odds ratio (DOR) was 5.17~621.0, respectively. SELDI-TOF-MS showed high accuracy in identifying NSCLC, and could be a potential screening tool for diagnosing NSCLC patients.

Multivalent Aptamer/Gold Nanoparticle–Modified Graphene Oxide for Mass Spectrometry–Based Tumor Tissue Imaging

“…S6 ). Compared to other mass spectrometry based tumor cell analysis techniques 8 , our Apt MUC1 –Au NPs/GO–LDI-MS platform is relatively simple, rapid, and selective and shows great legibility for tumor cells quantification.…”

Proteomic analysis of plasma exosomes in patients with non-small cell lung cancer

“…Although significant progress has been made in the diagnosis and treatment of lung cancer, patient prognosis remains unsatisfactory ( 3 , 4 ) and the overall survival rate of lung cancer patients being disappointingly low. There may be several factors contributing to this low overall survival rate, such as the lack of effective screening strategies to detect early tumors, the obvious drug resistance of lung cancer cells, and the insufficient understanding of the multifactor cell network activated or inhibited during the pathogenesis of cancer ( 5 ). Furthermore, the identification of a reliable biomarker to predict tumor response to treatments and patient prognosis remains elusive ( 6 ).…”

“…Figures 4,5 highlight the enriched GO and KEGG pathways for squamous-cell carcinoma and adenocarcinoma. The top 5 enriched GO terms of the differentially expressed proteins in lung squamous carcinoma and lung adenocarcinoma were highly similar.…”